0
0
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 - PR Newswire
9/10/22 at 1:00pm
Organization
PRNewswire
50 words
0
Comments
Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is...
You are the first to view
https://www.prnewswire.com/news-releases/i-mab-announces-positive-phase-2-data-of-lemzoparlimab-in-combination-with-azacitidine-aza-in-patients-with-higher-risk-myelodysplastic-syndrome-at-esmo-2022-301621532.html
Create an account or login to join the discussion